WHO recommends widespread use of world’s first ever African made malaria vaccine for children

AFRICAN scientists have been commended by the World Health Organisation for developing the world’s first and only malaria vaccine recommended for widespread use among children in Sub-Saharan Africa and other regions with moderate to high levels of transmission.
The recommendation, according to the WHO is based on results from an ongoing pilot programme in Ghana, Kenya and Malawi that has reached more than 800 000 children since 2019.
“This is a historic moment. The long-awaited malaria vaccine for children is a breakthrough for science, child health and malaria control,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year.”
The WHO chief expressed his delight at his organization’s recommendation in a thread on the WHO Twitter account on Wednesday, saying “this is a vaccine developed in Africa, by African scientists.” He thanked researchers on the continent in addition to British drug manufacturer GlaxoSmithKline, for helping develop the vaccine over the past 30 years, as well the Bill and Melinda Gates Foundation, which partially funded the project.
“Today, the RTS,S malaria vaccine — more than 30 years in the making — changes the course of public health history,” one of the tweets read. “We still have a very long road to travel. But this is a long stride down that road,” a follow-up post continued.
In a Wednesday news release, WHO’s regional director for Africa Dr Matshidiso Moeti said, “For centuries, malaria has stalked sub-Saharan Africa, causing immense personal suffering.
“We have long hoped for an effective malaria vaccine and now, for the first time ever, we have such a vaccine recommended for widespread use.

“Today’s recommendation offers a glimmer of hope for the continent which shoulders the heaviest burden of the disease and we expect many more African children to be protected from malaria and grow into healthy adults.”

The WHO recommended that the vaccine could be used to help protect children from the deadliest form of malaria, known as Plasmodium falciparum. It suggested delivering the vaccine in four doses to children from 5 months old.
Malaria is a parasitic disease transmitted through the bite of female Anopheles mosquitoes. Despite being both preventable and treatable, it is among the primary causes of childhood illness and death in sub-Saharan Africa, and more than 260,000 African children under the age of five die from malaria annually, according to WHO.
The vaccine works by stopping the malaria parasite maturing and multiplying in the liver, after which it would normally enter the patient’s bloodstream and trigger the disease symptoms.
Clinical trials have shown the vaccine offers a 39% protection against malaria in newborn children between the ages of five and 17 months.

Leave a Reply

Your email address will not be published. Required fields are marked *

0 Comments
scroll to top